Skip to main content

Table 1 Association of TXNRD1 and TXNIP RNA expression with metastasis-free survival

From: Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer

 

Prognostic factor

Pvalue

HR

95% CI

Mainz cohort

(n=200)

TXNRD1 RNA expression

0.032

1.920

1.058 to 3.486

 

TXNIP RNA expression

0.017

0.598

0.392 to 0.912

Rotterdam cohort

(n=286)

TXNRD1 RNA expression

0.004

1.755

1.196 to 2.576

 

TXNIP RNA expression

< 0.001

0.654

0.525 to 0.815

Transbig cohort

(n=302)

TXNRD1 RNA expression

0.021

1.692

1.084 to 2.642

 

TXNIP RNA expression

0.013

0.639

0.448 to 0.910

Combined cohort

(n=788)

TXNRD1 RNA expression

< 0.001

1.955

1.519 to 2.518

 

TXNIP RNA expression

< 0.001

0.642

0.554 to 0.743

  1. Thioredoxin reductase 1 (TXNRD1) RNA expression is associated with worse metastasis-free survival in patients with node-negative breast cancer in the univariate Cox analysis. In contrast, thioredoxin interacting protein (TXNIP) is associated with better metastasis-free survival. Results obtained in the Mainz cohort could be validated in the Rotterdam cohort and in the Transbig cohort of node-negative breast cancer patients. In the combined cohort of 788 patients, significant associations of TXNRD1 and TXNIP with metastasis-free survival were also obtained. HR: hazard ratio, CI, confidence interval.